APO-ATORVASTATIN 40 MG
ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 40 MG · DIN 02295296 · APOTEX INC
Health Canada status: MARKETED
What is APO-ATORVASTATIN?
APO-ATORVASTATIN 40 MG contains ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02295296, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-ATORVASTATIN used for?
Adjunct to diet for reduction of elevated lipids (Total-C, LDL-C, TG, apo B) in hyperlipidemic conditions and prevention of cardiovascular disease (myocardial infarction and stroke risk reduction).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02295296 |
|---|---|
| Brand name | APO-ATORVASTATIN |
| Generic / active ingredient | ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 40 MG |
| Manufacturer | APOTEX INC |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA05 ATORVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-May-2010 |
| Original market date | 2010-05-19 00:00:00 |
How is it administered?
10-80 mg once daily. Adjust at 2-4 week intervals. Pediatric (10-17 yrs): 10 mg starting, max 20 mg/day. Take any time of day with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (Section 11 mentioned in TOC but text cuts off). Standard practice for this drug is 15-30°C.
How is it supplied?
Bottles of 90, 100, and 500 tablets; blisters of 30.
Contraindications
Hypersensitivity; active liver disease; unexplained persistent transaminase elevations >3x ULN; pregnancy; breastfeeding; concomitant use of hepatitis C antivirals or cyclosporine.
Warnings and precautions
Risk of myopathy/rhabdomyolysis; monitor liver enzymes; risk of hemorrhagic stroke in patients with recent stroke/TIA; potential for increased fasting glucose/HbA1c levels.
Is ATORVASTATIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA05 ATORVASTATIN. 87 of 216 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ATORVASTATIN CALCIUM | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457741 |
| ACH-ATORVASTATIN CALCIUM | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457768 |
| ACH-ATORVASTATIN CALCIUM | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457776 |
| ACH-ATORVASTATIN CALCIUM | 80 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457784 |
| APO-ATORVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02295261 |
| APO-ATORVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02295288 |
| APO-ATORVASTATIN | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02295318 |
| ATORVASTATIN | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02346486 |
| ATORVASTATIN | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02348705 |
| ATORVASTATIN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02506076 |
Who else supplies ATORVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATORVASTATIN appears in 2136 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.